Effects of Ivabradine on Cardiovascular Events in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction. A Three-Year Randomised Double-Blind Placebo-Controlled International Multicentre Study

Trial Profile

Effects of Ivabradine on Cardiovascular Events in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction. A Three-Year Randomised Double-Blind Placebo-Controlled International Multicentre Study

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Ivabradine (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Left ventricular dysfunction
  • Focus Registrational; Therapeutic Use
  • Acronyms BEAUTIFUL
  • Most Recent Events

    • 28 Oct 2009 Results of new sub-analyses were presented today at the 2009 Canadian Cardiovascular Congress, according to a Montreal Heart Institute media release.
    • 31 Aug 2009 Subgroup results presented at ESC 2009, as reported in a Servier media release.
    • 31 Aug 2008 Results presented at ESC 2008 and published in the Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top